Two INSERM research teams led by
Pier1 Vincenzo
Piazza2 and Giovanni Marsicano (INSERM Unit 862 "Neurocentre Magendie" in Bordeaux) recently discovered that
pregnenolone(孕烯醇酮), a
molecule3 produced by the brain, acts as a natural defence
mechanism4 against the harmful effects of cannabis in animals. Pregnenolone prevents THC, the main active principle in cannabis, from
fully5 activating6 its brain receptor, the CB1 receptor, that when overstimulated by THC causes the
intoxicating7 effects of cannabis. By identifying this mechanism, the INSERM teams are already developing new approaches for the treatment of cannabis
addiction8. These results are to be published in Science on 3 January.
Over 20 million people around the world are
addicted9 to cannabis, including a little more than a half million people in France. In the last few years, cannabis addiction has become one of the main reasons for seeking treatment in addiction clinics. Cannabis consumption is particularly high (30%) in individuals between 16 to 24 years old, a population that is especially
susceptible10 to the harmful effects of the drug.
While cannabis consumers are seeking a state of
relaxation11,
well-being12 and altered perception, there are many dangers associated to a regular consumption of cannabis. Two major behavioural problems are associated with regular cannabis use in humans:
cognitive13 deficits14 and a general loss of motivation. Thus, in addition to being extremely dependent on the drug, regular users of cannabis show signs of memory loss and a lack of motivation that make quite hard their social insertion.
The main active ingredient in cannabis, THC, acts on the brain through CB1 cannabinoid receptors located in the neurons. THC
binds15 to these receptors diverting them from their
physiological16 roles, such as regulating food
intake17,
metabolism18, cognitive processes and pleasure. When THC overstimulates CB1 receptors, it triggers a reduction in memory abilities, motivation and gradually leads to
dependence19.